Loading...
XHELORNBV
Market cap6.19bUSD
Dec 20, Last price  
42.78EUR
1D
1.25%
1Q
-9.35%
Jan 2017
1.16%
IPO
210.00%
Name

Orion Oyj

Chart & Performance

D1W1MN
XHEL:ORNBV chart
P/E
27.35
P/S
4.98
EPS
1.56
Div Yield, %
3.79%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
4.01%
Revenues
1.19b
-11.27%
1,946,200,0001,901,800,000311,200,000683,600,000710,700,000771,500,000849,900,000917,900,000980,300,0001,006,900,0001,015,300,0001,015,600,0001,073,500,0001,084,700,000977,400,0001,050,900,0001,078,100,0001,041,000,0001,340,700,0001,189,600,000
Net income
217m
-37.97%
90,500,000131,100,00066,600,000145,400,000136,300,000151,400,000184,700,000209,500,000208,900,000206,200,000211,300,000208,200,000249,000,000226,000,000330,300,000200,400,000219,900,000193,800,000349,500,000216,800,000
CFO
119m
-72.61%
185,300,000173,300,00081,600,000150,900,000144,400,000204,600,000209,100,000198,900,000221,000,000215,200,000296,700,000254,900,000249,100,000228,400,000230,900,000270,800,000299,100,000215,700,000434,400,000119,000,000
Dividend
Oct 15, 20240.81 EUR/sh
Earnings
Feb 25, 2025

Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
URL
https://www.orion.fi/
IPO date
Jul 03, 2006
Employees
3,657
Domiciled in
FI
Incorporated in
FI

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,189,600
-11.27%
1,340,700
28.79%
1,041,000
-3.44%
Cost of revenue
958,400
906,600
804,100
Unusual Expense (Income)
NOPBT
231,200
434,100
236,900
NOPBT Margin
19.44%
32.38%
22.76%
Operating Taxes
55,100
90,800
48,500
Tax Rate
23.83%
20.92%
20.47%
NOPAT
176,100
343,300
188,400
Net income
216,800
-37.97%
349,500
80.34%
193,800
-11.87%
Dividends
(224,900)
(211,200)
(211,200)
Dividend yield
4.08%
2.93%
4.11%
Proceeds from repurchase of equity
(17,900)
BB yield
0.25%
Debt
Debt current
29,000
17,200
3,800
Long-term debt
179,100
204,900
113,200
Deferred revenue
66,900
68,700
11,900
Other long-term liabilities
14,000
12,300
6,300
Net debt
101,100
(111,800)
(115,400)
Cash flow
Cash from operating activities
119,000
434,400
215,700
CAPEX
(65,600)
(73,100)
(85,000)
Cash from investing activities
(108,400)
(154,300)
(80,200)
Cash from financing activities
(243,200)
(159,800)
(214,800)
FCF
(6,000)
233,200
179,400
Balance
Cash
106,700
332,600
216,700
Long term investments
300
1,300
15,700
Excess cash
47,520
266,865
180,350
Stockholders' equity
902,200
942,900
771,100
Invested Capital
1,123,480
928,935
681,850
ROIC
17.16%
42.63%
28.79%
ROCE
19.22%
35.06%
26.43%
EV
Common stock shares outstanding
140,361
140,590
140,547
Price
39.29
-23.32%
51.24
40.31%
36.52
-2.69%
Market cap
5,514,785
-23.45%
7,203,832
40.35%
5,132,776
-2.66%
EV
5,615,885
7,092,032
5,022,376
EBITDA
282,700
481,600
282,700
EV/EBITDA
19.87
14.73
17.77
Interest
5,700
1,500
1,000
Interest/NOPBT
2.47%
0.35%
0.42%